 Tuberculosis, Multidrug-Resistant
"Tuberculosis, Multidrug-Resistant" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Tuberculosis resistant to chemotherapy with two or more ANTITUBERCULAR AGENTS, including at least ISONIAZID and RIFAMPICIN. The problem of resistance is particularly troublesome in tuberculous OPPORTUNISTIC INFECTIONS associated with HIV INFECTIONS. It requires the use of second line drugs which are more toxic than the first line regimens. TB with isolates that have developed further resistance to at least three of the six classes of second line drugs is defined as EXTENSIVELY DRUG-RESISTANT TUBERCULOSIS.
| Descriptor ID |
D018088
|
| MeSH Number(s) |
C01.252.410.040.552.846.775
|
| Concept/Terms |
Tuberculosis, Multidrug-Resistant- Tuberculosis, Multidrug-Resistant
- Multidrug-Resistant Tuberculosis
- Tuberculosis, Multidrug Resistant
- Tuberculosis, MDR
- MDR Tuberculosis
- Tuberculosis, Multi-Drug Resistant
- Multi-Drug Resistant Tuberculosis
- Tuberculosis, Multi Drug Resistant
|
Below are MeSH descriptors whose meaning is more general than "Tuberculosis, Multidrug-Resistant".
Below are MeSH descriptors whose meaning is more specific than "Tuberculosis, Multidrug-Resistant".
This graph shows the total number of publications written about "Tuberculosis, Multidrug-Resistant" by people in this website by year, and whether "Tuberculosis, Multidrug-Resistant" was a major or minor topic of these publications.
To see the data from this visualization as text, click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1995 | 1 | 0 | 1 | | 2004 | 0 | 1 | 1 | | 2007 | 0 | 1 | 1 |
To return to the timeline, click here.
Below are the most recent publications written about "Tuberculosis, Multidrug-Resistant" by people in Profiles.
-
Farhat MR, Mitnick CD, Franke MF, Kaur D, Sloutsky A, Murray M, Jacobson KR. Concordance of Mycobacterium tuberculosis fluoroquinolone resistance testing: implications for treatment. Int J Tuberc Lung Dis. 2015 Mar; 19(3):339-41.
-
Mitnick CD, Franke MF, Rich ML, Alcantara Viru FA, Appleton SC, Atwood SS, Bayona JN, Bonilla CA, Chalco K, Fraser HS, Furin JJ, Guerra D, Hurtado RM, Joseph K, Llaro K, Mestanza L, Mukherjee JS, Muñoz M, Palacios E, Sanchez E, Seung KJ, Shin SS, Sloutsky A, Tolman AW, Becerra MC. Aggressive regimens for multidrug-resistant tuberculosis decrease all-cause mortality. PLoS One. 2013; 8(3):e58664.
-
Cohen T, Murray M, Abubakar I, Zhang Z, Sloutsky A, Arteaga F, Chalco K, Franke MF, Becerra MC. Multiple introductions of multidrug-resistant tuberculosis into households, Lima, Peru. Emerg Infect Dis. 2011 Jun; 17(6):969-75.
-
Kam KM, Sloutsky A, Yip CW, Bulled N, Seung KJ, Zignol M, Espinal M, Kim SJ. Determination of critical concentrations of second-line anti-tuberculosis drugs with clinical and microbiological relevance. Int J Tuberc Lung Dis. 2010 Mar; 14(3):282-8.
-
Mitnick CD, Shin SS, Seung KJ, Rich ML, Atwood SS, Furin JJ, Fitzmaurice GM, Alcantara Viru FA, Appleton SC, Bayona JN, Bonilla CA, Chalco K, Choi S, Franke MF, Fraser HS, Guerra D, Hurtado RM, Jazayeri D, Joseph K, Llaro K, Mestanza L, Mukherjee JS, Muñoz M, Palacios E, Sanchez E, Sloutsky A, Becerra MC. Comprehensive treatment of extensively drug-resistant tuberculosis. N Engl J Med. 2008 Aug 7; 359(6):563-74.
-
Eisenhuber E, Mostbeck G, Bankier A, Stadler A, Rumetshofer R. [Radiologic diagnosis of lung tuberculosis]. Radiologe. 2007 May; 47(5):393-400.
-
Han LL, Sloutsky A, Canales R, Naroditskaya V, Shin SS, Seung KJ, Timperi R, Becerra MC. Acquisition of drug resistance in multidrug-resistant Mycobacterium tuberculosis during directly observed empiric retreatment with standardized regimens. Int J Tuberc Lung Dis. 2005 Jul; 9(7):818-21.
-
Timperi R, Han LL, Sloutsky A, Becerra MC, Nardell EA, Salazar JJ, Smith-Fawzi MC. Drug resistance profiles of Mycobacterium tuberculosis isolates: five years' experience and insight into treatment strategies for MDR-TB in Lima, Peru. Int J Tuberc Lung Dis. 2005 Feb; 9(2):175-80.
-
Rengarajan J, Sassetti CM, Naroditskaya V, Sloutsky A, Bloom BR, Rubin EJ. The folate pathway is a target for resistance to the drug para-aminosalicylic acid (PAS) in mycobacteria. Mol Microbiol. 2004 Jul; 53(1):275-82.
-
Mukherjee JS, Joseph JK, Rich ML, Shin SS, Furin JJ, Seung KJ, Sloutsky A, Socci AR, Vanderwarker C, Vasquez L, Palacios E, Guerra D, Viru FA, Farmer P, Del Castillo HE. Clinical and programmatic considerations in the treatment of MDR-TB in children: a series of 16 patients from Lima, Peru. Int J Tuberc Lung Dis. 2003 Jul; 7(7):637-44.
|
People  People who have written about this concept. _
Similar Concepts
People who have written about this concept.
_
Top Journals
Top journals in which articles about this concept have been published.
|